Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules. We show 17 historical shares outstanding datapoints in our VIR shares outstanding history coverage, used to compute VIR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VIR market cap history over the course of time is important for investors
interested in comparing VIR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VIR versus a peer is one thing; comparing
VIR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VIR can fluctuate over the course of history.
With this page we aim to empower investors researching VIR by allowing them to research the VIR market cap history. |
Free VIR Email Alerts:
Video: The Importance of Market Cap
